Emerging from the UK, retatrutide, a novel compound , is creating considerable excitement within the healthcare community regarding its promise for body management . This dual GIP and GLP-1 receptor agonist seems to provide a considerable advantage over existing therapies, showing promising results in initial clinical trials . Researchers suggest i